VBI Vaccines Profit Margin 2016-2021 | VBIV
Current and historical gross margin, operating margin and net profit margin for VBI Vaccines (VBIV) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. VBI Vaccines net profit margin as of June 30, 2021 is -7014.58%.
|VBI Vaccines Annual Profit Margins
|VBI Vaccines Quarterly Profit Margins
||Medical - Biomedical and Genetics
VBI Vaccines Inc. is a biopharmaceutical company developing novel technologies to expand vaccine protection. The company's eVLP vaccine platform allows for the design of enveloped virus-like particle vaccines which closely mimic the target virus. Its lead eVLP asset is a prophylactic cytomegalovirus vaccine. Its second platform is a thermostable technology that enables the development of vaccines and biologics. VBI Vaccines Inc., formerly known as SciVac Therapeutics, Inc., is headquartered in Cambridge, MA.